In addition, RAS gene mutation is the predominant oncogenic defect in poorly differentiated thyroid carcinoma
(PDTC), found in 20% to 55% of cases, while it is only found in approximately 12% to 17% of ATCs.
Background: The clinical behavior and management of poorly differentiated thyroid carcinoma (PDTC) are very different from papillary thyroid carcinoma (PTC).
Malignant tumors of thyroid follicular cell origin are categorized as well-differentiated thyroid carcinoma (WDTC), consisting the majority of papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma, poorly differentiated thyroid carcinoma (PDTC), and undifferentiated/anaplastic thyroid carcinoma (ATC).
Unusual finding on ultrasonography of follicular thyroid carcinoma including poorly differentiated thyroid carcinoma.
1 They made a differentiation between poorly differentiated thyroid carcinoma
Only one case of poorly differentiated thyroid carcinoma was negative on core and positive on the whole section.
Cytokeratin 19 expression was noted in 9 of 22 papillary thyroid carcinomas and 1 of 2 poorly differentiated thyroid carcinomas.
HBME1 expression was noted in 20 of 23 papillary thyroid carcinomas, both poorly differentiated thyroid carcinomas, and 1 of 21 normal thyroids.
Clinicopathological significance of poorly differentiated thyroid carcinoma.
6) These neoplasms were termed poorly differentiated thyroid carcinomas (PDTCs) in their original description in the early 1980s.
Poorly differentiated thyroid carcinomas, defined mainly on the basis of growth pattern alone (such as the tumors reported in the large Italian study by Volante et al (36)), also occupy an intermediate prognostic position in the spectrum of thyroid carcinoma progression; however, survival of patients is much better when their definition is applied to PDTCs than when our definition is applied on the basis of mitoses and necrosis.
E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas